Company
Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing and commercializing proprietary pharmaceuticals that improve the treatment of cancer and other life-threatening illnesses. Cantex’s pipeline consists of two product candidates – DSTAT (formerly known as CX-01) and Dicopp®. Both drugs are in clinical development for diseases where innovative and more effective treatments are greatly needed.
16055
page-template,page-template-full_width,page-template-full_width-php,page,page-id-16055,page-parent,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode_grid_1200,qode-theme-ver-18.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.5,vc_responsive
 

Company

doctor reviewing MRI

ABOUT CANTEX PHARMACEUTICALS, INC.

Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing and commercializing proprietary pharmaceuticals that improve the treatment of cancer and other life-threatening illnesses. Cantex’s pipeline consists of two product candidates – DSTAT (formerly known as CX-01) and Dicopp®. Both drugs are in clinical development for diseases where innovative and more effective treatments are greatly needed.

 

DSTAT was licensed to Chimerix, Inc. in July 2019 and is being studied in two disease indications – acute lung injury (ALI) in COVID-19 patients and acute myeloid leukemia (AML). Cantex remains involved in the continued development of DSTAT via a Joint Development Committee.

 

In COVID-19 associated ALI, DSTAT is currently the subject of an ongoing Phase 2/3 clinical trial. This program is based upon pre-clinical data that suggest DSTAT may reduce inflammation, decrease immune cell infiltration and prevent and treat coagulation disorders associated with ALI.

 

DSTAT is also being studied as a potential treatment for AML. A randomized Phase 2 clinical trial in AML indicated that DSTAT + 7+3 improves event-free and relapse-free survival as well as overall survival without additive toxicity. Importantly, most patients who achieved a complete response remained relapse free 15+ months after initial treatment. A Phase 3 clinical trial in AML is expected to begin in late 2020.

 

Dicopp®, which is a proprietary combination of disulfiram + copper, is being developed for the treatment of metastatic pancreatic cancer, recurrent/refractory multiple myeloma, and recurrent pediatric sarcoma. A Phase 2 study of Dicopp® in metastatic pancreatic cancer in progress, while a Phase 1/2 study of Dicopp® in recurrent/refractory multiple myeloma and in recurrent pediatric sarcoma expected to begin in the second half of 2020.